查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1882970

儿童疫苗市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2024-2032 年）

Pediatric Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 159 Pages | 商品交期: 请询问到货日

价格

儿童疫苗市场成长驱动因素

全球儿童疫苗市场正经历强劲增长，这主要得益于儿童免疫计划的扩展、政府支持的增加以及对疫苗可预防疾病的日益重视。根据本报告，儿童疫苗市场预计将在 2024 年达到 453.6 亿美元，2025 年将成长至 468.6 亿美元，并在 2032 年达到 950.4 亿美元。这意味着 2025 年至 2032 年的复合年增长率 (CAGR) 将达到 10.6%。 2024 年，北美以 43.23% 的市占率领先。这主要归功于其强大的医疗保健体系、较高的疫苗接种率以及频繁的新产品上市。

儿童疫苗在预防小儿麻痹、麻疹、疟疾、肺炎球菌疾病和腮腺炎等危及生命的疾病以及增强儿童免疫力方面发挥着至关重要的作用。葛兰素史克（GSK plc）、默克公司（Merck & Co., Inc.）和赛诺菲（Sanofi）等大型公司正在扩大产能以满足不断增长的全球需求，从而为市场提供了支持。各国政府和非营利组织不断增加投资，旨在保护儿童免受疫苗可预防疾病的侵害，这进一步推动了市场扩张。例如，盖兹基金会于2025年6月宣布，将在五年内投资16亿美元，以支持全球疫苗免疫联盟（Gavi）的全球免疫计画。

市场动态

驱动因素

政府支持力度的加大和大规模儿童疫苗接种计划是推动市场发展的关键因素。联合国儿童基金会（UNICEF）和全球疫苗免疫联盟（GAVI）等国际组织与各国政府合作，购买疫苗并提供免疫服务。例如，2025年1月，全球疫苗免疫联盟（GAVI）报告称，自2023年以来，联合国儿童基金会已向17个非洲国家的儿童提供了超过980万剂疟疾疫苗。这代表着全球儿童疫苗接种计画的扩展。

阻碍因素

儘管全球需求不断增长，但疫苗犹豫仍然是许多中低收入国家广泛采用疫苗的障碍。错误讯息、对医疗系统的不信任、文化障碍以及医疗设施的匮乏都促使了疫苗接种率低。 2019年，世界卫生组织将疫苗犹豫列为全球十大健康威胁之一，而自新冠疫情爆发以来，这种不信任程度进一步加剧。

机会

由于针对目前尚无核准疫苗的疾病的研发工作不断推进，存在着巨大的机会。拉沙热和产肠毒素大肠桿菌 (ETEC) 等高传染性疾病持续影响成千上万的儿童。根据美国国立卫生研究院 (NIH) 2024 年 2 月发布的报告，拉沙热每年促使 5,000 人死亡，新增病例达 10 万至 30 万例，但目前尚无核准疫苗。这种未被满足的需求正在推动全球疫苗研发管线的扩张。

挑战

儿科疫苗市场面临的一大挑战是低收入地区缺乏冷链储存和物流基础设施。根据 "人人享有永续能源" (SEforALL) 2021 年发布的一份报告，由于供应链限制和冷藏设施不可靠，27 亿人无法可靠地获得疫苗，促使疫苗浪费和供应有限。

市场趋势

最重要的趋势之一是联合疫苗在全球的推广。这减少了儿童所需的注射次数，简化了免疫接种程序，并提高了整体疫苗接种覆盖率。例如，2025年7月，全球疫苗免疫联盟（GAVI）在茅利塔尼亚和塞内加尔推出了六价疫苗，可预防六种疾病，取代了传统的五价疫苗和小儿麻痹灭活疫苗（IPV）。

细分市场亮点

2024年，重组疫苗、结合疫苗和次单位疫苗因其高效性和监管支持而占市场主导地位。减毒活疫苗、灭活疫苗、mRNA疫苗、病毒载体疫苗和类毒素疫苗也因强大的研发管线和不断扩大的审批范围而需求强劲。

依疾病类型划分，由于麻疹、德国麻疹、小儿麻痹、人类乳突病毒（HPV）和流感的高感染率，病毒性疾病疫苗占了最大的市场占有率。随着雅培公司于 2024 年推出 PneumoShield 14，预计细菌性疾病疫苗市场将稳定成长。

口服疫苗因其易于接种且适用于大规模疫苗接种计划而占市场主导地位，而注射疫苗则凭藉先进的给药技术持续扩张。

区域展望

北美巩固了其领先地位，预计 2024 年收入将达到 196.1 亿美元，这主要得益于其强大的基础设施和创新能力。欧洲维持较高的疫苗接种覆盖率，但面临供应缺口。同时，由于疾病爆发和疫苗需求不断增长，预计亚太地区将实现最快增长。拉丁美洲和中东/非洲地区在世界卫生组织和全球疫苗免疫联盟 (GAVI) 支持的计画下继续扩大规模。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键洞察

  • 主要国家和地区的监管环境
  • 主要国家和地区的疫苗接种覆盖率
  • 主要国家和地区的政府儿童免疫计划
  • 儿童疫苗市场的技术进步
  • 主要产业趋势（併购、合作、新产品发表）等等）

第五章：全球儿童疫苗市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 按类型划分
    • 减毒活疫苗
    • 灭活​​疫苗
    • 重组/结合/次单位疫苗
    • mRNA疫苗
    • 病毒载体疫苗
    • 类毒素疫苗
    • 其他
  • 市场分析、洞察与预测 - 按疾病划分
    • 病毒性疾病
      • 甲型肝炎
      • 肝炎B
      • 小儿麻痹
      • 呼吸道合胞病毒 (RSV)
      • 流感
      • 人类乳突病毒 (HPV)
      • 麻疹、腮腺炎、德国麻疹 (MMR)
      • 轮状病毒
      • 带状疱疹
      • 其他
    • 细菌性疾病
      • 肺炎链球菌感染
      • 百白破疫苗 (DTP)
      • 脑膜炎双球菌感染
      • 其他
  • 市场分析、洞察与预测 - 按给药途径
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测 - 按分销管道
    • 医院和零售药局
    • 政府供应商
    • 其他
  • 市场分析、洞察与预测 - 按地区
    • 北部美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美儿童疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲儿童疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚半岛
    • 欧洲其他地区

第八章：亚太地区儿童疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章 拉丁美洲儿童疫苗市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章 中东与非洲儿童疫苗市场分析、洞察与预测（2019-2032）

  • 依国家/地区
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家/地区

第十一章：竞争分析

  • 全球市占率分析 (2024)
  • 公司简介
    • 默克公司 (Merck & Co., Inc.)
    • 赛诺菲 (Sanofi)
    • 巴拉特生技公司 (Bharat Biotech)
    • 葛兰素史克公司 (GSK plc.)
    • 中国科兴生物 (SINOVAC)
    • 印度血清研究所 (Serum Institute of India Pvt. Ltd.)
    • 哈夫金生物製药股份有限公司 (HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.)
    • 帕纳西亚生物技术公司 (Panacea Biotec)
    • Bio Farma
    • AJ Vaccines A/S
    • 北京生物製品研究所有限公司 (Beijing Institute of Biological Products Co., Ltd.)
Product Code: FBI113756

Growth Factors of pediatric vaccines Market

The global pediatric vaccines market is experiencing strong growth driven by rising childhood immunization programs, expanding government support, and increasing focus on vaccine-preventable diseases. According to the report, the pediatric vaccines market size stood at USD 45.36 billion in 2024, and is projected to increase to USD 46.86 billion in 2025, before reaching USD 95.04 billion by 2032, reflecting a robust CAGR of 10.6% from 2025 to 2032. In 2024, North America dominated the market with a 43.23% share, owing to strong healthcare systems, high immunization coverage, and frequent product launches.

Pediatric vaccines play a crucial role in strengthening immunity among children and preventing life-threatening diseases such as polio, measles, malaria, pneumococcal infections, mumps, and more. The market is supported by major companies- including GSK plc., Merck & Co., Inc., and Sanofi-that are expanding production capacity to meet rising global demand. Increasing government and nonprofit investments aimed at protecting children from vaccine-preventable diseases further fuel market expansion. For instance, in June 2025, the Gates Foundation invested USD 1.60 billion over five years to support Gavi's vaccination programs worldwide.

Market Dynamics

Drivers

Growing government support and large-scale childhood vaccination programs are major drivers of the market. International organizations such as UNICEF and GAVI collaborate with governments to procure vaccines and deliver immunization services. As an example, GAVI reported in January 2025 that since 2023, UNICEF has delivered over 9.8 million malaria vaccine doses to children across 17 African nations. This highlights the increasing scale of pediatric immunization initiatives globally.

Restraints

Despite strong worldwide demand, vaccine hesitancy continues to hinder adoption in many low- and middle-income countries. Misinformation, mistrust in healthcare systems, cultural barriers, and limited access to medical facilities contribute to low vaccination rates. WHO identified vaccine hesitancy as one of the top ten global health threats in 2019, and levels of mistrust have increased since the COVID-19 pandemic.

Opportunities

Significant opportunities exist through growing research and development initiatives targeting diseases that currently lack approved vaccines. Highly contagious diseases such as Lassa fever and Enterotoxigenic E. coli (ETEC) continue to affect thousands of children. As per a February 2024 NIH report, Lassa fever causes 5,000 deaths annually and accounts for 100,000-300,000 cases each year, with no approved vaccine available yet. This unmet need is encouraging global expansion of vaccine research pipelines.

Challenges

A major challenge for the pediatric vaccines market is the lack of cold chain storage and logistics infrastructure in low-income regions. According to a 2021 report by Sustainable Energy for All, 2.7 billion people lack dependable access to vaccines due to supply chain limitations and unreliable cold storage-leading to vaccine wastage and reduced accessibility.

Market Trends

One of the most significant trends is the increasing global shift toward combination vaccines, which reduce the number of injections children require, simplify immunization schedules, and improve overall vaccination coverage. For example, in July 2025, GAVI introduced a hexavalent vaccine in Mauritania and Senegal that protects against six diseases, replacing previous pentavalent and IPV vaccines.

Segmentation Highlights

The recombinant/conjugate/subunit vaccine type dominated the market in 2024 due to high effectiveness and regulatory support. Live attenuated, inactivated, mRNA, viral vector, and toxoid vaccines are also witnessing strong demand driven by robust research pipelines and expanding approvals.

By disease indication, viral disease vaccines held the largest share owing to the high prevalence of measles, rubella, polio, HPV, and influenza. Bacterial disease vaccines are set to grow steadily, supported by new launches like Abbott's PneumoShield 14 in 2024.

The oral route leads the market due to ease of administration and suitability for mass immunization programs, while parenteral vaccines continue to expand with advanced delivery technologies.

Regional Outlook

North America generated USD 19.61 billion in revenue in 2024, solidifying its leadership through strong infrastructure and innovation. Europe maintains high immunization rates but faces supply gaps, while Asia Pacific is expected to grow fastest due to rising disease outbreaks and vaccination demand. Latin America and the Middle East & Africa continue to expand through WHO and GAVI-supported programs.

Conclusion

With the market expected to rise from USD 45.36 billion in 2024 to USD 95.04 billion by 2032, the pediatric vaccines industry remains on a strong growth trajectory. Government funding, technological advancements, and expanding immunization programs will continue to drive global market momentum through 2032.

Segmentation By Type

  • Live Attenuated
  • Inactivated
  • Recombinant/Conjugate/Subunit
  • mRNA Vaccine
  • Viral Vectors Vaccines
  • Toxoid
  • Others

By Disease Indication

  • Viral Diseases
    • Hepatitis
    • Hepatitis A
    • Hepatitis B
    • Polio
    • RSV
    • Influenza
    • HPV
    • Measles/Mumps/Rubella
    • Rotavirus
    • Shingles (Herpes Zoster)
    • Others
  • Bacterial Diseases
    • Pneumococcal Diseases
    • DTP
    • Meningococcal Diseases
    • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country)
    • Germany
    • U.K
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Disease Indication, Route of Administration, Distribution Channel, and Country /sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regulatory Scenarios, By Key Countries/Regions
  • 4.2. Vaccination Coverage- By Key Countries/ Regions
  • 4.3. Government Immunization Programs for Children- By Key Countries/ Regions
  • 4.4. Technological Advancements in Pediatric Vaccines Market
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Live Attenuated
    • 5.1.2. Inactivated
    • 5.1.3. Recombinant/Conjugate/Subunit
    • 5.1.4. mRNA Vaccine
    • 5.1.5. Viral Vectors Vaccines
    • 5.1.6. Toxoid
    • 5.1.7. Others
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Viral Diseases
      • 5.2.1.1. Hepatitis A
      • 5.2.1.2. Hepatitis B
      • 5.2.1.3. Polio
      • 5.2.1.4. RSV
      • 5.2.1.5. Influenza
      • 5.2.1.6. HPV
      • 5.2.1.7. MMR
      • 5.2.1.8. Rotavirus
      • 5.2.1.9. Shingles
      • 5.2.1.10. Others
    • 5.2.2. Bacterial Diseases
      • 5.2.2.1. Pneumococcal Diseases
      • 5.2.2.2. DTP
      • 5.2.2.3. Meningococcal Diseases
      • 5.2.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital & Retail Pharmacies
    • 5.4.2. Government Suppliers
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Live Attenuated
    • 6.1.2. Inactivated
    • 6.1.3. Recombinant/Conjugate/Subunit
    • 6.1.4. mRNA Vaccine
    • 6.1.5. Viral Vectors Vaccines
    • 6.1.6. Toxoid
    • 6.1.7. Others
  • 6.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 6.2.1. Viral Diseases
      • 6.2.1.1. Hepatitis A
      • 6.2.1.2. Hepatitis B
      • 6.2.1.3. Polio
      • 6.2.1.4. RSV
      • 6.2.1.5. Influenza
      • 6.2.1.6. HPV
      • 6.2.1.7. MMR
      • 6.2.1.8. Rotavirus
      • 6.2.1.9. Shingles
      • 6.2.1.10. Others
    • 6.2.2. Bacterial Diseases
      • 6.2.2.1. Pneumococcal Diseases
      • 6.2.2.2. DTP
      • 6.2.2.3. Meningococcal Diseases
      • 6.2.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital & Retail Pharmacies
    • 6.4.2. Government Suppliers
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Live Attenuated
    • 7.1.2. Inactivated
    • 7.1.3. Recombinant/Conjugate/Subunit
    • 7.1.4. mRNA Vaccine
    • 7.1.5. Viral Vectors Vaccines
    • 7.1.6. Toxoid
    • 7.1.7. Others
  • 7.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 7.2.1. Viral Diseases
      • 7.2.1.1. Hepatitis A
      • 7.2.1.2. Hepatitis B
      • 7.2.1.3. Polio
      • 7.2.1.4. RSV
      • 7.2.1.5. Influenza
      • 7.2.1.6. HPV
      • 7.2.1.7. MMR
      • 7.2.1.8. Rotavirus
      • 7.2.1.9. Shingles
      • 7.2.1.10. Others
    • 7.2.2. Bacterial Diseases
      • 7.2.2.1. Pneumococcal Diseases
      • 7.2.2.2. DTP
      • 7.2.2.3. Meningococcal Diseases
      • 7.2.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital & Retail Pharmacies
    • 7.4.2. Government Suppliers
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Live Attenuated
    • 8.1.2. Inactivated
    • 8.1.3. Recombinant/Conjugate/Subunit
    • 8.1.4. mRNA Vaccine
    • 8.1.5. Viral Vectors Vaccines
    • 8.1.6. Toxoid
    • 8.1.7. Others
  • 8.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 8.2.1. Viral Diseases
      • 8.2.1.1. Hepatitis A
      • 8.2.1.2. Hepatitis B
      • 8.2.1.3. Polio
      • 8.2.1.4. RSV
      • 8.2.1.5. Influenza
      • 8.2.1.6. HPV
      • 8.2.1.7. MMR
      • 8.2.1.8. Rotavirus
      • 8.2.1.9. Shingles
      • 8.2.1.10. Others
    • 8.2.2. Bacterial Diseases
      • 8.2.2.1. Pneumococcal Diseases
      • 8.2.2.2. DTP
      • 8.2.2.3. Meningococcal Diseases
      • 8.2.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital & Retail Pharmacies
    • 8.4.2. Government Suppliers
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Live Attenuated
    • 9.1.2. Inactivated
    • 9.1.3. Recombinant/Conjugate/Subunit
    • 9.1.4. mRNA Vaccine
    • 9.1.5. Viral Vectors Vaccines
    • 9.1.6. Toxoid
    • 9.1.7. Others
  • 9.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 9.2.1. Viral Diseases
      • 9.2.1.1. Hepatitis A
      • 9.2.1.2. Hepatitis B
      • 9.2.1.3. Polio
      • 9.2.1.4. RSV
      • 9.2.1.5. Influenza
      • 9.2.1.6. HPV
      • 9.2.1.7. MMR
      • 9.2.1.8. Rotavirus
      • 9.2.1.9. Shingles
      • 9.2.1.10. Others
    • 9.2.2. Bacterial Diseases
      • 9.2.2.1. Pneumococcal Diseases
      • 9.2.2.2. DTP
      • 9.2.2.3. Meningococcal Diseases
      • 9.2.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital & Retail Pharmacies
    • 9.4.2. Government Suppliers
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Pediatric Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Live Attenuated
    • 10.1.2. Inactivated
    • 10.1.3. Recombinant/Conjugate/Subunit
    • 10.1.4. mRNA Vaccine
    • 10.1.5. Viral Vectors Vaccines
    • 10.1.6. Toxoid
    • 10.1.7. Others
  • 10.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 10.2.1. Viral Diseases
      • 10.2.1.1. Hepatitis A
      • 10.2.1.2. Hepatitis B
      • 10.2.1.3. Polio
      • 10.2.1.4. RSV
      • 10.2.1.5. Influenza
      • 10.2.1.6. HPV
      • 10.2.1.7. MMR
      • 10.2.1.8. Rotavirus
      • 10.2.1.9. Shingles
      • 10.2.1.10. Others
    • 10.2.2. Bacterial Diseases
      • 10.2.2.1. Pneumococcal Diseases
      • 10.2.2.2. DTP
      • 10.2.2.3. Meningococcal Diseases
      • 10.2.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital & Retail Pharmacies
    • 10.4.2. Government Suppliers
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Merck & Co., Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bharat Biotech.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. GSK plc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. SINOVAC
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Serum Institute of India Pvt. Ltd.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Panacea Biotec
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bio Farma
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. AJ Vaccines A/S
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Beijing Institute of Biological Products Co., Ltd.
      • 11.2.11.1. Overview
      • 11.2.11.2. Products & services
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 2: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 3: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 4: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 5: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 6: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 7: Global Pediatric Vaccines Market Revenue (USD billion) Forecast, By Region, 2019-2032
  • Table 8: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 9: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 10: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 11: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 12: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 13: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 14: North America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032
  • Table 15: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 16: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 17: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 18: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 19: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 20: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 21: Europe Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 22: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 23: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 24: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 25: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 26: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 27: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 28: Asia Pacific Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 29: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 30: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 31: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 32: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 33: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 34: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 35: Latin America Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
  • Table 36: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Type, 2019-2032
  • Table 37: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Disease Indication, 2019-2032
  • Table 38: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Viral Diseases, 2019-2032
  • Table 39: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Bacterial Diseases, 2019-2032
  • Table 40: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Distribution Channel, 2019-2032
  • Table 41: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Route of Administration, 2019-2032
  • Table 42: Middle East & Africa Pediatric Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Pediatric Vaccines Market Revenue Breakdown (USD billion, %), By Region, 2024 & 2032
  • Figure 2: Global Pediatric Vaccines Market Value Share (%), By Type, 2024 & 2032
  • Figure 3: Global Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024 & 2032
  • Figure 4: Global Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024 & 2032
  • Figure 5: Global Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024 & 2032
  • Figure 6: Global Pediatric Vaccines Market Value Share (%), By Region, 2024 & 2032
  • Figure 7: North America Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 8: North America Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 9: North America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 10: North America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 11: North America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 12: North America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 13: North America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 14: North America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 15: North America Pediatric Vaccines Market Value (USD billion), By Country, 2024 & 2032
  • Figure 16: North America Pediatric Vaccines Market Value Share (%), By Country, 2024
  • Figure 17: Europe Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 18: Europe Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 19: Europe Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 20: Europe Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 21: Europe Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 22: Europe Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 23: Europe Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 24: Europe Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 25: Europe Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 26: Europe Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 27: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 28: Asia Pacific Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 29: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 30: Asia Pacific Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 31: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 32: Asia Pacific Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 33: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 34: Asia Pacific Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 35: Asia Pacific Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 36: Asia Pacific Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 37: Latin America Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 38: Latin America Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 39: Latin America Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 40: Latin America Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 41: Latin America Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 42: Latin America Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 43: Latin America Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 44: Latin America Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 45: Latin America Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 46: Latin America Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 47: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Type, 2024 & 2032
  • Figure 48: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Type, 2024
  • Figure 49: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Disease Indication, 2024 & 2032
  • Figure 50: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Disease Indication, 2024
  • Figure 51: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Route of Administration, 2024 & 2032
  • Figure 52: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Route of Administration, 2024
  • Figure 53: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Distribution Channel, 2024 & 2032
  • Figure 54: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Distribution Channel, 2024
  • Figure 55: Middle East & Africa Pediatric Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
  • Figure 56: Middle East & Africa Pediatric Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 57: Global Pediatric Vaccines Market Share (%), By Company, 2024